The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Phase I safety and pharmacokinetic (PK) dose escalation study with SAR245408 (S) polymorph E, a PI3K inhibitor, in patients (pts) with solid tumors or lymphoma.

Oliver Edgar  Bechter

Consulting or Advisory Role - Novartis

Speakers' Bureau - Amgen; Novartis; Roche Pharma AG

Herlinde  Dumez

No Relationships to Disclose

Jo  Costermans

No Relationships to Disclose

Kevin  Punie

No Relationships to Disclose

Li  Liu

Employment - Sanofi

Jason  Jiang

Employment - Sanofi

Jean-François  Dedieu

Employment - Sanofi

Patrick  Schöffski

Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boston Biomedical; GlaxoSmithKline; Novartis; Plexxikon; SERVIER

Speakers' Bureau - GlaxoSmithKline; Novartis